Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program

Pediatric Blood and Cancer

Volumn 60, Issue 7, 2013, Pages

  Lock, Richard B ^a   Carol, Hernan ^a   Maris, John M ^b   Kang, Min H ^c   Reynolds, C Patrick ^c   Kolb, E Anders ^d   Gorlick, Richard ^e   Keir, Stephen T ^f   Billups, Catherine A ^g   Kurmasheva, Raushan T ^h   Houghton, Peter J ^h   Smith, Malcolm A ⁱ  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^e CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^h NATIONWIDE CHILDREN S HOSPITAL   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Developmental therapeutics; Hsp90 inhibitors; Preclinical testing

Indexed keywords

B RAF KINASE; GANETESPIB; JANUS KINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NONHUMAN; OUTCOME ASSESSMENT; PILOCYTIC ASTROCYTOMA; PRIORITY JOURNAL; SARCOMA; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878264535     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24451     Document Type: Article

References (23)

1. Cullinan SB, Whitesell L. Heat shock protein 90: A unique chemotherapeutic target. Semin Oncol 2006; 33: 457-465.
2. Grbovic OM, Basso AD, Sawai A, et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 2006; 103: 57-62.
3. Kim HL, Cassone M, Otvos L, Jr., et al. HIF-1alpha and STAT3 client proteins interacting with the cancer chaperone Hsp90: Therapeutic considerations. Cancer Biol Ther 2008; 7: 10-14.
4. Normant E, Paez G, West KA, et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 2011; 30: 2581-2586.
5. Weigert O, Lane AA, Bird L, et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med 2012; 209: 259-273.
6. Ying W, Du Z, Sun L, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 2012; 11: 475-484.
7. Zhou D, Teofilovici F, Liu Y, et al. Associating retinal drug exposure and retention with the ocular toxicity profiles of Hsp90 inhibitors. J Clin Oncol 2012; 30 (suppl; abstr 3086).
8. Wong K, Koczywas M, Goldman JW, et al. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2011; 29 (suppl; abstr 7500).
9. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer 2006; 49: 928-940.
10. Frgala T, Kalous O, Proffitt RT, et al. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 2007; 6: 886-897.
11. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 2007; 50: 37-45.
12. Liem NL, Papa RA, Milross CG, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004; 103: 3905-3914.
13. Kang MH, Reynolds CP, Houghton PJ, et al. Initial testing (stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer 2011; 59: 185-188.
14. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program. Pediatr Blood Cancer 2010; 55: 668-677.
15. Solit DB, Osman I, Polsky D, et al. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 2008; 14: 8302-8307.
16. De Brouwer S, De Preter K, Kumps C, et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 2010; 16: 4353-4362.
17. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455: 930-935.
18. Sasaki T, Okuda K, Zheng W, et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 2010; 70: 10038-10043.
19. Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010; 115: 5312-5321.
20. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009; 41: 1243-1246.
21. Chen IM, Harvey RC, Mullighan CG, et al. Outcome modeling with CRLF2, IKZF1, JAK and minimal residual disease in pediatric acute lymphoblastic leukemia: A Children's Oncology Group Study. Blood 2012; 119: 3512-3522.
22. Carol H, Lock R, Maris J, et al. Pediatric Preclinical Testing Program (PPTP) evaluation of the JAK inhibitor AZD1480. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research 2012:LB-318.
23. Smith MA, Morton CL, Phelps DA, et al. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 51: 34-41.